All In Biotech

BLA 761028 · Amgen INC

Mvasi

Bevacizumab-Awwb · Injection · Vascular Endothelial Growth Factor Inhibitor

Last checked: Nov 20, 2026Latest source record: Feb 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 14, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,998

508 Phase 3, 455 recruiting

FAERS reports

4,692

1,397 serious, 144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2026.

MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) 1.1 Metastatic Colorectal Cancer MVASI, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC). MVASI, in...

Mechanism: Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MVASI · BEVACIZUMAB-AWWB 400MG/16ML (25MG/ML) · INJECTABLE, INJECTION · Prescription
  • MVASI · BEVACIZUMAB-AWWB 100MG/4ML (25MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bevacizumab" as an intervention, any sponsor and status, largest first.

All 2,998 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use502
  • product storage error437
  • circumstance or information capable of leading to medication error346
  • hypertension215
  • disease progression195
  • blood pressure increased181
  • product dose omission issue158
  • adverse event145
  • fatigue130
  • platelet count decreased130
  • nausea108
  • diarrhoea99

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20161
20171
201928
2020299
2021805
2022846
20231,008
2024797
2025612
2026294

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mvasi (Bevacizumab-Awwb)

2024 spending

$16.1M

Beneficiaries

540

3,060 claims

Per beneficiary

$29,780

$167.86 per unit

View as table
YearSpending
2020$2,276,416
2021$4,457,805
2022$9,966,935
2023$12,655,424
2024$16,081,199

Part B: Mvasi (Bevacizumab-Awwb) · HCPCS Q5107

2024 spending

$141M

Beneficiaries

13,212

75,604 claims

Per beneficiary

$10,697

2024 ASP limit $26.39 per unit

View as table
YearSpending
2020$308,006,313
2021$336,344,276
2022$205,032,451
2023$163,203,025
2024$141,325,402

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,932 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.